To complement the initial findings, we expanded the GSEA-based analysis to identify significantly upregulated or downregulated pathways in ROS1+ lung adenocarcinomas and cell lines in comparison to ALK/RET+ tumor samples (Figure 1F). This evidence concerns the gene ROS1 and lung adenocarcinoma.